From: Poor medical care for people with migraine in Europe – evidence from the Eurolight study
Country | N | Using triptans (of all with migraine) n (%) | Migraine on ≥5 days/month n (%) | Using preventative medication (of those with migraine on ≥5 days/month) n (%) | Consulting health professionals n (%) | |||
---|---|---|---|---|---|---|---|---|
Specialist | General practitioner | Non-medical | None | |||||
Studies with a general-population basis | ||||||||
Germany | 109 | 12 (11.0) | 42 (38.5) | 1 (2.4) | 7 (6.4) | 14 (12.8) | 5 (4.6) | 83 (76.1) |
Italy | 221 | 14 (6.3) | 61 (27.6) | 1 (1.6) | 14 (6.3) | 21 (9.5) | 15 (6.8) | 171 (77.4) |
Lithuania | 149 | 5 (3.4) | 62 (41.6) | 2 (3.2) | 16 (10.7) | 23 (15.4) | 2 (1.3) | 108 (72.5) |
Luxemburg | 669 | 48 (7.2) | 219 (32.7) | 10 (4.6) | 39 (5.8) | 105 (15.7) | 27 (4.0) | 498 (74.4) |
Netherlands-population | 815 | 75 (9.2) | 171 (20.8) | 11 (6.4) | 25 (3.1) | 106 (13.0) | 36 (4.4) | 648 (79.5) |
Spain-workplace | 401 | 90 (22.4) | 153 (38.2) | 21 (13.7) | 60 (15.0) | 72 (18.0) | 28 (7.0) | 241 (60.1) |
Studies conducted in general practice settings | ||||||||
Austria | 263 | 37 (14.1) | 106 (40.3) | 7 (6.6) | 46 (17.5) | 26 (10.0) | 14 (5.3) | 177 (67.3) |
France | 337 | 46 (13.6) | 91 (27.0) | 4 (4.4) | 7 (2.1) | 81 (24.0) | 22 (6.5) | 227 (67.3) |
UK | 49 | 12 (24.5) | 22 (44.9) | 2 (9.1) | 11 (22.4) | 7 (14.3) | 0 (0) | 31 (63.3) |
Studies among members of lay headache organizations | ||||||||
Ireland | 152 | 94 (61.8) | 78 (51.3) | 23 (29.5) | 34 (22.4) | 45 (29.6) | 6 (3.9) | 67 (44.1) |
Netherlands-lay | 195 | 133 (68.2) | 120 (61.5) | 50 (41.7) | 66 (33.8) | 26 (13.3) | 21 (11.0) | 82 (42.1) |
Spain-lay | 106 | 49 (46.2) | 50 (47.2) | 8 (16.0) | 25 (23.6) | 27 (25.5) | 10 (9.4) | 44 (41.5) |